Home »

Can-Fite BioPharma Successfully Concludes $6,000,000 Public Offering With an Over-Subscription of 300%

Company Expects to Apply to List Its U.S. ADRs on the NYSE MKT

Can-Fite BioPharma-s CF101 Drug Selected as one of the “Top Autoimmune/Anti-Inflammatory Disease Projects to Watch” by Elsevier Business Intelligence

CF101 Is Currently in Phase III Trials for Psoriasis and Phase II for Rheumatoid Arthritis

Can-Fite BioPharma to Present Its Liver Cancer Drug at the 18th World Congress on Advances in Oncology in Greece

Phase II Trial to Commence Under FDA Orphan Drug Designation

Can-Fite-s Subsidiary OphthaliX to Present at Ophthalmology Futures European Forum

To Showcase Clinical Data on CF101 for Treatment of Glaucoma

Can-Fite CEO Pnina Fishman Interviewed on CorporateProfile.com

PETACH TIKVA, ISRAEL — (Marketwired) — 09/23/13 — (TASE: CFBI), (PINKSHEETS: CANFY), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Company-s CEO Dr. Pnina Fishman was recently interviewed on CorporateProfile.com.In the interview Dr. Fishman spoke about Can-Fite listing its shares in the U.S., the Company-s drug development pipeline, and the scientific basis for Can-Fite-s platform technolog

Analytics

© 2020 88Finance. All Rights Reserved. Log in - Copyright by LayerMedia


Blogverzeichnis - Blog Verzeichnis bloggerei.de Blog Top Liste - by TopBlogs.de